Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance.
Plasma concentrations of haloperidol and its reduced metabolite (reduced haloperidol) were investigated in cigarette smokers (N = 23) and nonsmokers (N = 27). Steady-state plasma concentrations were obtained 12 h post bedtime dose. Haloperidol and reduced haloperidol concentrations were determined by RIA. Reduced haloperidol was separated by selective succinylation and liquid chromatography. Patients were clinically assessed with the Clinical Global Impression Scale (CGIS). Smokers had significantly lower haloperidol and reduced haloperidol plasma concentrations than nonsmokers (P less than 0.01, P less than 0.05). Clearance of haloperidol was significantly greater in smokers compared to nonsmokers (P = 0.0052). CGIS assessments did not show significant differences between smokers and nonsmokers. Plasma concentrations should be carefully monitored when patients either start or stop smoking.
D000328:Adult; D005260:Female; D006220:Haloperidol / Q000097:blood*; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D010084:Oxidation-Reduction; D011863:Radioimmunoassay; D012189:Retrospective Studies; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy; D012907:Smoking
D006220:Haloperidol